Clinical Trials Logo

Filter by:
NCT ID: NCT01950871 Terminated - Prostate Cancer Clinical Trials

Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning

PHSTT-01
Start date: October 2013
Phase: Phase 4
Study type: Interventional

The primary objective of the PHSTT-01 trial is to determine if prostate HistoScanning (HS) analysis can be used to improve the detection of clinically significant prostate cancer (PCa), and potentially reduce the burden and number of biopsies in routine clinical practice. Prostate HS is an ultrasound-based tissue characterization technology specifically developed to detect, visualize, and locate tissue suspected of harboring PCa. These suspicious tissues are displayed as red areas on an imaging monitor. Recently a new biopsy guidance tool has been developed that uses the results of the prostate HS analysis. The subjects that will participate in this study are all scheduled for a first biopsy of the prostate. They will initially be imaged using transrectal ultrasound (TRUS) to obtain data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo a routine systematic 10- to 12-core biopsy procedure using TRUS. This will be followed by a TRUS-guided biopsy that uses the result of prostate HS analysis and new biopsy guidance tool.

NCT ID: NCT01948180 Terminated - EBV Clinical Trials

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

CITADEL
Start date: September 2014
Phase: Phase 2
Study type: Interventional

To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma

NCT ID: NCT01944839 Terminated - Clinical trials for Age-Related Macular Degeneration

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Start date: August 2013
Phase: Phase 3
Study type: Interventional

The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

NCT ID: NCT01941277 Terminated - Prediabetic State Clinical Trials

Effect of Exercise on Insulin Resistance

EFFORT
Start date: August 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of exercise on Insulin Resistance (IR) in subjects who do not routinely exercise and who are at risk of developing diabetes (prediabetes). It is estimated that approximately 30-90 people will participate in this study at three study sites in the United States and United Kingdom.

NCT ID: NCT01939223 Terminated - Clinical trials for Colorectal Neoplasms

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy

COAST
Start date: December 2, 2013
Phase: Phase 3
Study type: Interventional

To evaluate and compare the efficacy and safety of regorafenib versus placebo in subjects with colorectal cancer (CRC) after curative resection of liver metastasis and completion of all planned chemotherapy.

NCT ID: NCT01937130 Terminated - Liver Cirrhosis Clinical Trials

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Start date: September 2013
Phase: Phase 2
Study type: Interventional

The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function.

NCT ID: NCT01934816 Terminated - Healthy Subjects Clinical Trials

Incretin and KATP Channels

Start date: June 2013
Phase: N/A
Study type: Interventional

This study aims to examine the involvement of KATP channels on the microvascular actions of the incretin GLP-1 and its analogues in healthy individuals and to determine whether the acute oral administration of different KATP channel blockers which are oral medications for Type 2 diabetes such as Glibenclamide and Glimepiride differentially modulate the microvascular responses in these individuals.

NCT ID: NCT01934504 Terminated - Clinical trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)

AAV
Start date: December 2013
Phase: N/A
Study type: Observational

The goal of the study is to find biological markers (certain proteins or cellular markers found in a blood test) that will inform doctors which patients diagnosed with ANCA-associated vasculitis (AAV) are most likely to be able to stop their medications suppressing their immune systems and remain in remission.

NCT ID: NCT01934101 Terminated - Clinical trials for Arthritis, Rheumatoid

Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers

Start date: August 12, 2013
Phase: Phase 1
Study type: Interventional

Primary Objective: • To determine the safety and tolerability of single and multiple ascending oral doses of CHR-5154 in healthy volunteers. Secondary Objectives: - To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426. - To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.

NCT ID: NCT01931566 Terminated - Clinical trials for Mild Cognitive Impairment Due to Alzheimer's Disease

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

TOMMORROW
Start date: August 1, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.